The antifolates: Evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs

I. David Goldman, Shrikanta Chattopadhyay, Rongbao Zhao, Richard Moran

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

More than 50 years after the introduction of the dihydrofolate reductase inhibitor, methotrexate, new antifolates have emerged and have been incorporated into the chemotherapeutic armamentarium. These include pralatrexate, with the same target as methotrexate, but with enhanced properties, and pemetrexed, with different enzyme targets and properties. Current synthetic efforts are focused on developing antifolates that are selectively delivered to cancer cells, but not to normal proliferating cells, exploiting the different properties of folate transporters. In another novel approach, drugs structurally and mechanistically unrelated to folates are linked to and use folic acid as a carrier to be endocytosed by folate receptors and then released to inhibit their cellular targets. This review describes the evolution and current status of antifolate pharmacology and prospects for the development of the next generation of folate analogs.

Original languageEnglish (US)
Pages (from-to)1409-1423
Number of pages15
JournalCurrent Opinion in Investigational Drugs
Volume11
Issue number12
StatePublished - Dec 2010

Fingerprint

Folic Acid Antagonists
Membrane Transport Proteins
Folic Acid
Methotrexate
Pemetrexed
Folic Acid Transporters
Endocytosis
Pharmacology
Enzymes
Pharmaceutical Preparations
Neoplasms

Keywords

  • Aminopterin
  • antifolate
  • folate
  • folate receptor
  • methotrexate
  • PCFT
  • pemetrexed
  • pralatrexate
  • proton-coupled folate transporter
  • reduced folate carrier
  • RFC
  • SLC19A1
  • SLC46A1

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Cite this

@article{be0a49b9b89f41bfb7b2d9bf28bf0676,
title = "The antifolates: Evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs",
abstract = "More than 50 years after the introduction of the dihydrofolate reductase inhibitor, methotrexate, new antifolates have emerged and have been incorporated into the chemotherapeutic armamentarium. These include pralatrexate, with the same target as methotrexate, but with enhanced properties, and pemetrexed, with different enzyme targets and properties. Current synthetic efforts are focused on developing antifolates that are selectively delivered to cancer cells, but not to normal proliferating cells, exploiting the different properties of folate transporters. In another novel approach, drugs structurally and mechanistically unrelated to folates are linked to and use folic acid as a carrier to be endocytosed by folate receptors and then released to inhibit their cellular targets. This review describes the evolution and current status of antifolate pharmacology and prospects for the development of the next generation of folate analogs.",
keywords = "Aminopterin, antifolate, folate, folate receptor, methotrexate, PCFT, pemetrexed, pralatrexate, proton-coupled folate transporter, reduced folate carrier, RFC, SLC19A1, SLC46A1",
author = "Goldman, {I. David} and Shrikanta Chattopadhyay and Rongbao Zhao and Richard Moran",
year = "2010",
month = "12",
language = "English (US)",
volume = "11",
pages = "1409--1423",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "12",

}

TY - JOUR

T1 - The antifolates

T2 - Evolution, new agents in the clinic, and how targeting delivery via specific membrane transporters is driving the development of a next generation of folate analogs

AU - Goldman, I. David

AU - Chattopadhyay, Shrikanta

AU - Zhao, Rongbao

AU - Moran, Richard

PY - 2010/12

Y1 - 2010/12

N2 - More than 50 years after the introduction of the dihydrofolate reductase inhibitor, methotrexate, new antifolates have emerged and have been incorporated into the chemotherapeutic armamentarium. These include pralatrexate, with the same target as methotrexate, but with enhanced properties, and pemetrexed, with different enzyme targets and properties. Current synthetic efforts are focused on developing antifolates that are selectively delivered to cancer cells, but not to normal proliferating cells, exploiting the different properties of folate transporters. In another novel approach, drugs structurally and mechanistically unrelated to folates are linked to and use folic acid as a carrier to be endocytosed by folate receptors and then released to inhibit their cellular targets. This review describes the evolution and current status of antifolate pharmacology and prospects for the development of the next generation of folate analogs.

AB - More than 50 years after the introduction of the dihydrofolate reductase inhibitor, methotrexate, new antifolates have emerged and have been incorporated into the chemotherapeutic armamentarium. These include pralatrexate, with the same target as methotrexate, but with enhanced properties, and pemetrexed, with different enzyme targets and properties. Current synthetic efforts are focused on developing antifolates that are selectively delivered to cancer cells, but not to normal proliferating cells, exploiting the different properties of folate transporters. In another novel approach, drugs structurally and mechanistically unrelated to folates are linked to and use folic acid as a carrier to be endocytosed by folate receptors and then released to inhibit their cellular targets. This review describes the evolution and current status of antifolate pharmacology and prospects for the development of the next generation of folate analogs.

KW - Aminopterin

KW - antifolate

KW - folate

KW - folate receptor

KW - methotrexate

KW - PCFT

KW - pemetrexed

KW - pralatrexate

KW - proton-coupled folate transporter

KW - reduced folate carrier

KW - RFC

KW - SLC19A1

KW - SLC46A1

UR - http://www.scopus.com/inward/record.url?scp=79952738916&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952738916&partnerID=8YFLogxK

M3 - Article

C2 - 21154123

AN - SCOPUS:79952738916

VL - 11

SP - 1409

EP - 1423

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 12

ER -